Sie sind hier: Startseite Termine Biosimilars, Biobetters & Synthetic Scaffold Molecules
x
Um unsere Webseite für Sie optimal zu gestalten und fortlaufend verbessern zu können, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen zu Cookies erhalten Sie in unserer Datenschutzerklärung.

Biosimilars, Biobetters & Synthetic Scaffold Molecules

We would like to give you a thorough update on the new challenges and opportunities arising in connection with the revision of the overarching biosimilar guideline and the upcoming further guidelines/revisions. We would like to discuss with you the preclinical and clinical topics, as well as the quality requirements. Especially the challenging topic of comparability exercises will be addressed in detail. The new FDA follow-on biologics approach will also be covered by the programme.
  • We would like to give you a thorough update on the new challenges and opportunities arising in connection with the revision of the overarching biosimilar guideline and the upcoming further guidelines/revisions. We would like to discuss with you the preclinical and clinical topics, as well as the quality requirements. Especially the challenging topic of comparability exercises will be addressed in detail. The new FDA follow-on biologics approach will also be covered by the programme.

    Topics:

    - Biosimilars: non-clinical & clinical aspects

    - Biomarker, surrogates etc - minimizing or optimising the study programme?

    - Synthetic Scaffold Molecules & "biobetters" - always a stand alone marketing authorisation?

    - The new FDA follow-on biologics approach

    - Quality changes & comparability exercises according to the CHMP guidance documents

    50.9353747 6.957656
Wann 21.11.2012 um 09:30 bis
22.11.2012 um 15:00
Veranstaltungsort Dorint am Heumarkt
Stadt Köln
Kontaktname
Kontakttelefon 06221 500-680
Zielgruppe This seminar addresses the needs of managers in the pharmaceutical industry. Especially those working in the following areas will benefit from this event: marketing authorisation, clinical & preclinical trials, quality & analytics and law.
Termin übernehmen vCal
iCal

Topics:

- Biosimilars: non-clinical & clinical aspects

- Biomarker, surrogates etc - minimizing or optimising the study programme?

- Synthetic Scaffold Molecules & "biobetters" - always a stand alone marketing authorisation?

- The new FDA follow-on biologics approach

- Quality changes & comparability exercises according to the CHMP guidance documents

Direktbuchung

Weitere Informationen über diesen Termin…

FORUM · Institut für Management GmbH

Programm

1211232.pdf — PDF document, 349 kB (358,218 bytes)
Artikelaktionen